Pharmacokinetics describes how the body processes a drug over time, including the concentration it reaches in the bloodstream and how long it remains before being cleared. Source Adobe Stock.
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • A non-clinical pharmacokinetic bridging study found RC220 and earlier RC110 formulation deliver equivalent systemic drug exposure
  • Ratios of peak and total drug exposure of (E,E)-bisantrene fell within the pre-specified equivalence range
  • Non-clinical data support the use of the established RC110 clinical dataset
  • Helps establish dosing levels in the clinical development of RC220

Racura Oncology (ASX: RAC) has obtained positive results from a non-clinical pharmacokinetic (PK) bridging study into RC220, the company’s proprietary formulation of (E,E)-bisantrene – a pure, single-isomer, small-molecule anticancer agent.

The Watchlist — short video interviews with ASX leaders. Watch now.

The study compared RC220 and RC110, the earlier Racura formulation used in two investigator-sponsored Phase 2 clinical trials in relapsed or refractory (returned or treatment-resistant) acute myeloid leukaemia (R/R AML). The study found RC220 and RC110 produced equivalent systemic exposure to (E,E)-bisantrene.

Pharmacokinetics describes how the body processes a drug over time, including the concentration it reaches in the bloodstream and how long it remains before being cleared.

A PK bridging study tests whether two formulations of the same active drug produce the same drug exposure, so that clinical experience gained with one formulation can inform the development of the other.

“This nonclinical study was designed to answer a critical question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene,” CEO and MD, Dr Daniel Tillett, said.

“The findings provide an important bridge to the clinical experience with RC110, which produced a 40% response rate in two separate Phase 2 trials in heavily pre-treated AML patients.

“This bridging study supports our plans to evaluate RC220 in patients with AML in the Phase 2b/3 EMILI trial as well as our HARNESS and CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution of this important work.”

Dr Tillett said RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation excipients (non-drug ingredients).

RC220 was developed to allow bisantrene to be given through a peripheral vein in the arm or leg, rather than requiring the use of a central line (a catheter placed in a large vein near the heart).

The nonclinical bridging study in six animals used a crossover design, in which each animal received intravenous infusions of both RC110 and RC220 in random order, separated by a drug-free washout period, and so served as its own control. Frequent blood sampling was used to measure plasma (E,E)-bisantrene concentrations over time.

Equivalence was assessed using the standard regulatory approach for comparing drug formulations, which is the ratio of average RC220 to RC110 exposure (the geometric mean ratio, GMR, where 1.00 means identical exposure) and its 90% confidence interval (CI), against a pre-specified range of 0.80–1.25.

Across three consecutive days of dosing, the 90% CIs for both peak plasma concentration (Cmax) and total exposure (area under the concentration–time curve, AUC) fell within this range on every day with GMRs ranging from 0.971 to 1.057.

RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at the Sheba Medical Centre, Israel. In a Phase 2 trial, RC110 given alone produced an overall response rate (complete or partial responses) of 40% in 10 patients.

The AML trials gave RC110 as a daily infusion over multiple consecutive days. These nonclinical PK equivalence data, together with the identical active ingredient in the two products, support applying the RC110 clinical experience to the future development of RC220.

RAC was steady at $1.67 with a Mkt cap of $331.3M prior to markets opening.

Join the discussion: See what HotCopper users are saying about Racura Oncology and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

rac by the numbers
More From The Market Online

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…

Artrya expands US commercial momentum with five-year HonorHealth agreement

Atrya has signed a five-year commercial agreement with major Arizona health system HonorHealth and becomes fifth…

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

TruScreen Group advances Bangladesh opportunity to drive Indian subcontinent expansion

TruScreen Group has completed a successful product presentation and training visit to Dhaka, Bangladesh as part…